The role of inflammatory pathways in cancer-associated cachexia and radiation resistance

Molecular Cancer Research

Volumn 11, Issue 9, 2013, Pages 967-972

  Laine, Aaron ^a   Iyengar, Puneeth ^a   Pandita, Tej K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CELL DNA; CLODRONIC ACID; CORTICOSTEROID; CYCLIN D1; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLANT MEDICINAL PRODUCT; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; STAT3 PROTEIN; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR RECEPTOR; VASCULOTROPIN;

ACUTE PHASE RESPONSE; ANEMIA; ANOREXIA; ATHEROSCLEROSIS; BODY MASS; CACHEXIA; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CATARACT; DIABETES MELLITUS; DIET SUPPLEMENTATION; DNA DAMAGE; DNA REPAIR; FATIGUE; FATTY ACID OXIDATION; GLUCOSE TOLERANCE; HUMAN; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; IONIZING RADIATION; LEAN BODY WEIGHT; LIPID METABOLISM; LIPID STORAGE; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MUSCLE ATROPHY; MUSCLE INJURY; NATURAL KILLER CELL; NONHUMAN; OBESITY; PHENOTYPE; PREMATURE AGING; PRIORITY JOURNAL; PROADIPOCYTE; PROSTATE CANCER; PROTEOMICS; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SQUAMOUS CELL CARCINOMA; STABLE EXPRESSION; TREATMENT FAILURE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; TUMOR VOLUME; WEIGHT REDUCTION; WERNER SYNDROME; WILD TYPE;

ADIPOSE TISSUE; CACHEXIA; CYTOKINES; DISEASE PROGRESSION; HUMANS; INFLAMMATION; MUSCLE, SKELETAL; NEOPLASMS; RADIATION TOLERANCE; TUMOR MICROENVIRONMENT;

EID: 84884496448     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0189     Document Type: Review

References (75)

1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
2. Mantovani A. Cancer: inflaming metastasis. Nature 2009;457:36-7.
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
4. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013;339:286-91.
5. Bing C, Trayhurn P. Regulation of adipose tissue metabolismin cancer cachexia. Curr Opin Clin Nutr Metab Care 2008;11:201-7. (Pubitemid 351533891)
6. Buntzel J, Kuttner K. [Value of megestrol acetate in treatment of cachexia in head-neck tumors]. Laryngorhinootologie 1995;74:504-7.
7. Couch M, Lai V, Cannon T, Guttridge D, Zanation A, George J, et al. Cancer cachexia syndrome in head and neck cancer patients: part I. Diagnosis, impact on quality of life and survival, and treatment. Head Neck 2007;29:401-11. (Pubitemid 46623505)
8. Lees J. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care 1999;8:133-6.
9. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002;2: 862-71. (Pubitemid 37328904)
10. Walz DA. Cancer-related anorexia-cachexia syndrome. Clin J Oncol Nurs 2010;14:283-7.
11. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care 2005;8: 265-9. (Pubitemid 40586184)
12. Fearon KC, Moses AG. Cancer cachexia. Int J Cardiol 2002;85:73-81.
13. von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol 2002; 85:173-83.
14. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-95.
15. Ringborg U, Bergqvist D, Brorsson B, Cavallin-Stahl E, Ceberg J, Einhorn N, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001-summary and conclusions. Acta Oncol 2003;42:357-65. (Pubitemid 37193830)
16. Deorukhkar A, Krishnan S. Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol 2010;80:1904-14.
17. Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 2007;4:172-80. (Pubitemid 46358854)
18. Ma Z, Webb DJ, Jo M, Gonias SL. Endogenously produced urokinasetype plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 2001;114:3387-96. (Pubitemid 33009262)
19. Szumiel I. Intrinsic radiation sensitivity: cellular signaling is the key. Radiat Res 2008;169:249-58. (Pubitemid 351521760)
20. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007;6:789-801. (Pubitemid 46554549)
21. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003;22:5813-27. (Pubitemid 37176702)
22. Brach MA, Gruss HJ, Kaisho T, Asano Y, Hirano T, Herrmann F. Ionizing radiation induces expression of interleukin 6 by human fibroblasts involving activation of nuclear factor-kappa B. J Biol Chem 1993;268:8466-72. (Pubitemid 23118623)
23. Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P. The role of NFkappaBand NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 1993;268:25624-31.
24. Harant H, de Martin R, Andrew PJ, Foglar E, Dittrich C, Lindley IJ. Synergistic activation of interleukin-8 gene transcription by all-transretinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappaB. J Biol Chem 1996;271:26954-61. (Pubitemid 26359110)
25. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M. NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 1999; 19:2690-8. (Pubitemid 29144513)
26. Hunt CR, Ramnarain D, Horikoshi N, Iyengar P, Pandita RK, Shay JW, et al. Histone modifications and DNA double strand break repair after exposure to ionizing radiations. Radiat Res 2013;179: 383-92.
27. Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, et al. Enhanced radiosensitization and chemosensitization in NFkappaB- suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer 2004;108:912-21. (Pubitemid 38112622)
28. Raju U, Lu R, Noel F, Gumin GJ, Tofilon PJ. Failure of a second X-ray dose to activate nuclear factor kappaB in normal rat astrocytes. J Biol Chem 1997;272:24624-30. (Pubitemid 27418679)
29. Bonner JA, Trummell HQ, Willey CD, Plants BA, Raisch KP. Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma. Radiother Oncol 2009;92:339-44.
30. Kim KW, Mutter RW, Cao C, Albert JM, Shinohara ET, Sekhar KR, et al. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther 2006;5:2659-65. (Pubitemid 44848992)
31. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, et al. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008;8:4521-33.
32. Meng Y, Beckett MA, Liang H, Mauceri HJ, van Rooijen N, Cohen KS, et al. Blockade of tumor necrosis factor alpha signaling in tumorassociated macrophages as a radiosensitizing strategy. Cancer Res 2010;70:1534-43.
33. Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 2009; 3:263-8.
34. Mantovani G, Maccio A, Mura L, Massa E, Mudu MC, Mulas C, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000;78:554-61. (Pubitemid 32039615)
35. Brake DK, Smith EO, Mersmann H, Smith CW, Robker RL. ICAM-1 expression in adipose tissue: effects of diet-induced obesity in mice. Am J Physiol Cell 2006;291:C1232-9. (Pubitemid 44878594)
36. Yu R, KimCS,Kwon BS, Kawada T. Mesenteric adipose tissue-derived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity 2006;14:1353-62. (Pubitemid 46219660)
37. Biswas SK, Sodhi A. In vitro activation of murine peritoneal macrophages by monocyte chemoattractant protein-1: upregulation of CD11b, production of proinflammatory cytokines, and the signal transduction pathway. J Interferon Cytokine Res 2002;22: 527-38. (Pubitemid 34639143)
38. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, et al. Identity of tumour necrosis factor and the macrophase-secreted factor cachectin. Nature 1995;316:552-4.
39. Argiles JM, Busquets S, Lopez-Soriano FJ. Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol 2011;668 Suppl 1:S81-6.
40. Carmen GY, Victor SM. Signalling mechanisms regulating lipolysis. Cell Signal 2006;18:401-8.
41. Ro HS, Zhang L, Majdalawieh A, Kim SW, Wu X, Lyons PJ, et al. Adipocyte enhancer-binding protein 1modulates adiposity and energy homeostasis. Obesity 2007;15:288-302. (Pubitemid 46407309)
42. Constantinou C, Fontes de Oliveira CC, Mintzopoulos D, Busquets S, He J, Kesarwani M, et al. Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med 2011; 27:15-24.
43. Wang B, Trayhurn P. Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture. Pflugers Arch 2006;452: 418-27. (Pubitemid 43962051)
44. Kuroda K, Nakashima J, Kanao K, Kikuchi E, Miyajima A, Horiguchi Y, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 2007;69:113-7. (Pubitemid 46161697)
45. Staal-van den Brekel AJ, Dentener MA, Schols AM, Buurman WA, Wouters EF. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995;13:2600-5.
46. Maltoni M, Fabbri L, Nanni O, Scarpi E, Pezzi L, Flamini E, et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 1997;5:130-5. (Pubitemid 27163454)
47. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992;89:1681-4.
48. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 2004;111:592-5. (Pubitemid 39045327)
49. Fujimoto-Ouchi K, Tamura S, Mori K, Tanaka Y, Ishitsuka H. Establishment and characterization of cachexia-inducing and -noninducing clones of murine colon 26 carcinoma. Int J Cancer 1995;61:522-8.
50. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011;11:1663-8.
51. Inadera H, Nagai S, Dong HY, Matsushima K. Molecular analysis of lipid-depleting factor in a colon-26-inoculated cancer cachexia model. Int J Cancer 2002;101:37-45. (Pubitemid 34832995)
52. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
53. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010;21:11-9.
54. Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE 2011;6: e22538.
55. Das SK, Hoefler G. The role of triglyceride lipases in cancer associated cachexia. Trends Mol Med 2013;19:292-301.
56. Sauer LA, Dauchy RT. Stimulation of tumor growth in adult rats in vivo during acute streptozotocin-induced diabetes. Cancer Res 1987;47: 1756-61. (Pubitemid 17056671)
57. Sauer LA, Nagel WO, Dauchy RT, Miceli LA, Austin JE. Stimulation of tumor growth in adult rats in vivo during an acute fast. Cancer Res 1986;46:3469-75. (Pubitemid 16096893)
58. Sprong D, Janssen HL, Vens C, Begg AC. Resistance of hypoxic cells to ionizing radiation is influenced by homologous recombination status. Int J Radiat Oncol Biol Phys 2006;64:562-72. (Pubitemid 43083446)
59. Russell L, Forsdyke DR. A human putative lymphocyte G0/G1 switch gene containing a CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA Cell Biol 1991;10:581-91.
60. Yang X, Lu X, Lombes M, Rha GB, Chi YI, Guerin TM, et al. The G(0)/G (1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab 2010;11:194-205.
61. Zandbergen F, Mandard S, Escher P, Tan NS, Patsouris D, Jatkoe T, et al. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem J 2005;392:313-24. (Pubitemid 41796520)
62. Yang X, Zhang X, Heckmann BL, Lu X, Liu J. Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor-alpha (TNF-alpha)-induced lipolysis in adipocytes. J Biol Chem 2011;286:40477-85.
63. Yu CE, Oshima J, Fu YH, Wijsman EM, Hisama F, Alisch R, et al. Positional cloning of the Werner's syndrome gene. Science 1996;272: 258-62. (Pubitemid 26119137)
64. Mori S, Murano S, Yokote K, Takemoto M, Asaumi S, Take A, et al. Enhanced intra-abdominal visceral fat accumulation in patients with Werner's syndrome. Int J Obes Relat Metab Disord 2001;25:292-5.
65. Yokote K, Hara K, Mori S, Kadowaki T, Saito Y, Goto M. Dysadipocytokinemia in werner syndrome and its recovery by treatment with pioglitazone. Diabetes Care 2004;27:2562-3. (Pubitemid 39281424)
66. Honjo S, Yokote K, Fujishiro T, Maezawa Y, Sato S, Koshizaka M, et al. Early amelioration of insulin resistance and reduction of interleukin-6 in Werner syndrome using pioglitazone. J Am Geriatr Soc 2008;56: 173-4.
67. Baracos VE. Clinical trials of cancer cachexia therapy, now and hereafter. J Clin Oncol 2013;31:1257-8.
68. Bruera E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebocontrolled study. J Clin Oncol 2003;21:129-34.
69. Del Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol 2013; 31:1271-6.
70. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-7. (Pubitemid 46638896)
71. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-smallcell lung cancer. N Engl J Med 2010;363:733-42.
72. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene 2000;19:2791-5. (Pubitemid 30339230)
73. Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res 2011;17:2035-43.
74. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Haraguchi N, Inoue H, et al. Differential gene expression profiles of radioresistant pancreatic cancer cell lines established by fractionated irradiation. Int J Oncol 2006;28:705-13.
75. Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck-a systematic review and metaanalysis. Radiother Oncol 2011;100:22-32.